Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Auteurs

H.S. Rugo, F. André, T. Yamashita, H. Cerda, I. Toledano, S.M. Stemmer, J.C. Jurado, D. Juric, I. Mayer, E.M. Ciruelos, H. Iwata, P. Conte, M. Campone, C. Wilke, D. Mills, A. Lteif, M. Miller, F. Gaudenzi, S. Loibl